drugset / Trial / NCT07772921

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

NCT07772921 ↗

Phase 3 Recruiting 1100 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Timeline

Start
2026-08-20
Primary completion
2029-06-01
Completion
2029-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tilrekimig Monoclonal antibody — Subcutaneous

Indications